New Orleans – 5pm on Sunday at the annual meeting of the American Society of Hematology (ASH) saw the start of the oral sessions, where the latest research and clinical trial data is presented.

I attended the novel agents in lymphoma session, and this post offers some top-line “notes from the road” on the following presentations:

Abstract 85: Idelalisib Ph2 data in patients with double (Rituximab and Alkylating Agent) refractory indolent Non-Hodgkin Lymphoma (iNHL).

Abstract 86: SAR245409 Monotherapy in relapsed/refractory Follicular Lymphoma from phase 2 ARD12130 study.

Abstract 87: Phase 2 study of BAY 80-6946 (copanlisib) in relapsed/refactory, indolent or aggressive lymphomas.

Subscribers to premium content can read more below:

Posted by 

Purchase Access to Premium Content

PLEASE READ BEFORE YOU BUY. Click on blue icon to purchase a PERSONAL, INDIVIDUAL license to premium content. Please READ our TERMS OF USE before purchasing (link at bottom of page): You are NOT PERMITTED to share access or copies of posts. If you work for a CONSULTING FIRM, AGENCY, or are in PR, COMMUNICATIONS OR MEDIA (that includes JOURNALISTs & WRITERs), you cannot purchase an INDIVIDUAL license through this site without prior approval (even if your use is personal) and typically a CORPORATE license will be required. Please CONTACT US to discuss how you might use our content & obtain a quote for the appropriate license. Rates may change without notice and are non-refundable. If you in any doubt about whether you can buy through the blue icon, PLEASE CONTACT US first.